BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [PMID: 36338895 DOI: 10.3748/wjg.v28.i39.5691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Valentino MS, Marzuillo P, Esposito C, Bartiromo M, Nardolillo M, Villani AV, Maresca A, Furcolo G, Guarino S, Miraglia Del Giudice E, Di Sessa A. The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal Function. J Clin Med 2023;12. [PMID: 36902824 DOI: 10.3390/jcm12052037] [Reference Citation Analysis]
2 Griffett K, Burris TP. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Front Med (Lausanne) 2023;10:1102469. [PMID: 36817797 DOI: 10.3389/fmed.2023.1102469] [Reference Citation Analysis]
3 Theofilis P, Vordoni A, Tsimihodimos V, Kalaitzidis RG. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers. High Blood Press Cardiovasc Prev 2023;30:63-72. [PMID: 36626077 DOI: 10.1007/s40292-023-00558-5] [Reference Citation Analysis]
4 Theofilis P, Vordoni A, Kalaitzidis RG. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Metabolites 2022;12. [PMID: 36557281 DOI: 10.3390/metabo12121243] [Reference Citation Analysis]